Kurzrock, Razelle
Kantarjian, Hagop M.
Kesselheim, Aaron S.
Sigal, Ellen V.
Article History
Accepted: 29 November 2019
First Online: 4 February 2020
Competing interests
: R.K. receives research funding from Foundation Medicine, Genentech, Grifols, Guardant Health, Incyte, Konica Minolta, Merck Serono, Pfizer and Sequenom, and consultant fees from Actuate Therapeutics, Genentech, LOXO, NeoMed and X-Biotech. She receives speaker fees from Roche and has an equity interest in Curematch and IDbyDNA. H.M.K. has received research funding from Abbvie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi–Sankyo, Immunogen, Jazz pharma, Novartis and Pfizer, and declares honoraria from Abbvie, Actinium, Agios, Amgen, Pfizer and Takeda. The other contributors declare no competing interests.